A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube

Gynecologic Oncology

Volumn 132, Issue 3, 2014, Pages 517-525

  Herzog, Thomas J ^a   Monk, Bradley J ^b   Rose, Peter G ^c   Braly, Patricia ^d   Hines, Jeffrey F ^e   Bell, Maria C ^f   Wenham, Robert M ^g   Secord, Angeles Alvarez ^h   Roman, Lynda D ⁱ   Einstein, Mark H ^j   Drake, Richard D ^c   Childs, Barrett H ^k  

^a Columbia University NY Presbyterian Medical Center ^*  (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d Women's Cancer Care   (United States)

^e Wellstar Gynecologic Oncology   (United States)

^f Sioux Valley Clinic   (United States)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^j ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^k SANOFI   (France)

more..

Author keywords

Bevacizumab; Docetaxel; Fallopian tube carcinoma; Ovarian cancer; Oxaliplatin; Primary peritoneal cancer

Indexed keywords

BEVACIZUMAB; CA 125 ANTIGEN; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BRAIN DISEASE; COLON FISTULA; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CYTOREDUCTIVE SURGERY; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSGEUSIA; EMBOLISM; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENITAL BLEEDING; HEADACHE; HEALING IMPAIRMENT; HEMATOMA; HUMAN; HYPERALGESIA; HYPERTENSION; INTESTINE PERFORATION; INTRAOCULAR HEMORRHAGE; LACRIMATION DISORDER; LEUKOCYTE COUNT; LEUKOPENIA; LUNG EMBOLISM; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT HEMORRHAGE; SMALL INTESTINE OBSTRUCTION; SUBDURAL HEMATOMA; TREATMENT RESPONSE; URINARY TRACT INFECTION; UTERINE TUBE CARCINOMA; VAGINA BLEEDING; VERY ELDERLY; VOMITING; WOUND DEHISCENCE;

BEVACIZUMAB; DOCETAXEL; FALLOPIAN TUBE CARCINOMA; OVARIAN CANCER; OXALIPLATIN; PRIMARY PERITONEAL CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; TAXOIDS;

EID: 84896388779     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.01.035     Document Type: Article

References (22)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 1 2012 10 29
2. G.C. Stuart, H. Kitchener, M. Bacon, A. duBois, M. Friedlander, and J. Ledermann et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference Int J Gynecol Cancer 21 4 2011 750 755
3. G. Ferrandina, M. Ludovisi, R. De Vincenzo, V. Salutari, D. Lorusso, and M. Colangelo et al. Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study Ann Oncol 18 8 2007 1348 1353
4. G. Seliger, L.P. Mueller, T. Kegel, E.J. Kantelhardt, A. Grothey, and R. Groe et al. Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer Int J Gynecol Cancer 19 8 Nov 2009 1446 1453
5. P.A. Vasey, G.C. Jayson, A. Gordon, H. Gabra, R. Coleman, and R. Atkinson et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma J Natl Cancer Inst 96 22 2004 1682 1691
6. J.L. Misset, P. Vennin, P.H. Chollet, P. Pouillart, P.H. Laplaige, and J.L. Frobert et al. Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients Ann Oncol 12 10 2001 1411 1415
7. R.A. Burger, M.W. Sill, B.J. Monk, B.E. Greer, and J.I. Sorosky Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 33 2007 5165 5171
8. S.A. Cannistra, U.A. Matulonis, R.T. Penson, J. Hambleton, J. Dupont, and H. Mackey et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 33 2007 5180 5186 [Erratum in: J Clin Oncol. 2008;26(10):1773]
9. J.P. Micha, B.H. Goldstein, M.A. Rettenmaier, M. Genesen, C. Graham, and K. Bader et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer Int J Gynecol Cancer 17 4 2007 771 776
10. R.A. Burger, M.F. Brady, M.A. Bookman, G.F. Fleming, B.J. Monk, and H. Huang et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 26 2011 2473 2483
11. T.J. Perren, A.M. Swart, J. Pfisterer, J.A. Ledermann, E. Pujade-Lauraine, and G. Kristensen et al. A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 26 2011 2484 2496
12. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 2 2000 205 216
13. G.J. Rustin, M. Quinn, T. Thigpen, A. du Bois, E. Pujade-Lauraine, and A. Jakobsen et al. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer) J Natl Cancer Inst 96 6 2004 487 488
14. Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 3.0 Available from: http://ctep.cancer.gov/protocolDevelopment/ electronic-applications/docs/ctcaev3.pdf
15. H. Ozer, J.O. Armitage, C.L. Bennett, J. Crawford, G.D. Demetri, and P.A. Pizzo et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel J Clin Oncol 18 20 2000 3558 3585
16. E.L. Kaplan, and P. Meier Non parametric estimation from incomplete observations J Am Stat Assoc 53 282 1958 457 481
17. National Cancer Institute Ovarian Epithelial Cancer Treatment (PDQ), Health Professional Version. Stage III and stage IV ovarian epithelial cancer treatment Available from: http://www.cancer.gov/cancertopics/pdq/treatment/ ovarianepithelial/HealthProfessional/page5 June 22, 2012
18. S.C. Rubin, P. Sabbatini, and A.N. Viswanathan Ovarian cancer R. Pazdur, L.D. Wagman, K.A. Camphausen, W.J. Hoskins, Cancer Management: A Multidisciplinary Approach 13th ed. March 25, 2011 UBM Medical LLC London, UK [Available from: http://www.cancernetwork.com/display/article/10165/1802681 ]
19. R.T. Penson, D.S. Dizon, S.A. Cannistra, M.R. Roche, C.N. Krasner, and S.T. Berlin et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors J Clin Oncol 28 1 2010 154 159
20. J.A. Konner, D.M. Grabon, S.R. Gerst, A. Iasonos, H. Thaler, and S.D. Pezzulli et al. Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer J Clin Oncol 29 35 2011 4662 4668
21. M.A. Bookman, M.F. Brady, W.P. McGuire, P.G. Harper, D.S. Alberts, and M. Friedlander et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup J Clin Oncol 27 9 2009 1419 1425 [Erratum in: J Clin Oncol 2009;27(13):2305]
22. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, and R.A. Burger et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 17 2003 3194 3200